抑癌基因 p53：生物学、信号通路和治疗靶点。
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
机构信息
Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02912, United States of America; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, United States of America; The Joint Program in Cancer Biology, Brown University and Lifespan Health System, Providence, RI 02912, United States of America; Cancer Center at Brown University, Warren Alpert Medical School, Brown University, Providence, RI 02912, United States of America.
Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02912, United States of America; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, United States of America; The Joint Program in Cancer Biology, Brown University and Lifespan Health System, Providence, RI 02912, United States of America; Cancer Center at Brown University, Warren Alpert Medical School, Brown University, Providence, RI 02912, United States of America.
出版信息
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188556. doi: 10.1016/j.bbcan.2021.188556. Epub 2021 Apr 29.
TP53 is the most commonly mutated gene in human cancer with over 100,000 literature citations in PubMed. This is a heavily studied pathway in cancer biology and oncology with a history that dates back to 1979 when p53 was discovered. The p53 pathway is a complex cellular stress response network with multiple diverse inputs and downstream outputs relevant to its role as a tumor suppressor pathway. While inroads have been made in understanding the biology and signaling in the p53 pathway, the p53 family, transcriptional readouts, and effects of an array of mutants, the pathway remains challenging in the realm of clinical translation. While the role of mutant p53 as a prognostic factor is recognized, the therapeutic modulation of its wild-type or mutant activities remain a work-in-progress. This review covers current knowledge about the biology, signaling mechanisms in the p53 pathway and summarizes advances in therapeutic development.
TP53 是人类癌症中最常见的突变基因，在 PubMed 中有超过 10 万篇文献引用。这是癌症生物学和肿瘤学中一个深入研究的途径，其历史可以追溯到 1979 年 p53 被发现的时候。p53 途径是一个复杂的细胞应激反应网络，有多个不同的输入和下游输出，与它作为肿瘤抑制途径的作用有关。尽管在理解 p53 途径的生物学和信号转导方面已经取得了一些进展，包括 p53 家族、转录读数以及一系列突变体的影响，但在临床转化方面，该途径仍然具有挑战性。虽然突变型 p53 作为预后因素的作用已得到认可，但对其野生型或突变型活性的治疗调节仍在进行中。这篇综述涵盖了关于 p53 途径的生物学、信号机制的最新知识，并总结了治疗开发方面的进展。
Zotero 插件